In Colombia, the first Coronavirus Infectious Disease 19 (COVID-19) case was detected and confirmed on March, 2020, on a person traveling from Italy. The country has since then experienced several waves of SARS-CoV-2 infections. Since the beginning of the pandemic, more than five million cases and 129,487 fatal cases had been reported by the Colombian Ministerio de Salud y Protección Social by the end of 2021 1,2. The third wave that occurred from April to July, 2021, was the more severe in Colombia, with the highest incidence and deaths reported up to date 3.
The analysis of the genomic surveillance during the third wave demonstrated that the variant of interest (VOI) mu was the country’s most important lineage of the SARS-CoV-2 4. Indeed, the Colombian Instituto Nacional de Salud characterized the emergence of the B.1.621 lineage in January, 2021, which was identified as the VOI Mu by the World Health Organization (WHO). Furthermore, the characterization has shown that mutations in the spike protein, such as E484K, N501Y, and P681H, could be related to the disease burden and its epidemiological impact 3.
The pandemic mostly affected the low-to-middle-income population because of its economic impact. Since the country has had long periods of lockdowns and travel restrictions, the government needed to reopen many restricted activities. Overall, the economic reopening, the progressive erosion of biosafety and insulation standards and the emergence of the mu variant could have been the most important factors related to the strength of the third wave in the country.
During the third wave, a group of co-workers presented signs and symptoms associated with SARS-CoV-2 infection. They had previously been appointed at the same time for the first dose of vaccine against COVID-19 in Medellín (the capital of the department of Antioquia, Colombia). The facilities and conditions of the vaccination room did not allow strict compliance with the regulations of distancing, ventilation and waiting time.
These conditions, added to the evidence of the transmission of SARS- CoV-2 mainly by aerosols and small droplets during close contacts, and the time between the vaccination and the onset of symptoms in the group of workers, makes us to suspect that they acquired the infection in the vaccination room due to the aforementioned conditions 5,6. A study was designed with the aim of characterizing epidemiologically, virologically and molecularly this outbreak of COVID-19.
Materials and methods
This was a retrospective, descriptive, transversal study.
Sample collection and analysis
We interviewed 24 co-workers who attended the appointment for their first vaccination dose. Demographics and clinical data from the people involved in the study were obtained through social networks and virtual meetings with the workmates.
After the vaccination and the suspected contagion, 13 out of 24 coworkers underwent COVID-19 diagnostic testing (antigen and/or RT-qPCR) in different health institutions in Medellín (table 1). Furthermore, nasopharyngeal swabs samples were obtained from four co-workers and a family member of the index case, five to eleven days after the vaccination, for additional SARS- CoV-2 studies, including further antigen/RT-qPCR testing, viral isolation and sequencing. Informed consent was obtained from each participant.
Person | Mask type and other protection | Age/Sex | Antigen test | qPCR | Date of onset of symptoms | Symptoms and Evolution |
---|---|---|---|---|---|---|
# 5 | One layer cloth mask | 49/Female | ND* | Negative | NA** | No symptoms |
# 6 | Three layer cloth mask | 63/Female | ND | Positive | 12-04-21 | Fever, cough, chills, sweating, myalgias, fatigue, dyspnea, pneumonia |
# 10 | One layer cloth mask and safety glasses | ND | Negative | ND | NA | No symptoms |
# 12 | N95 | 54/Male | ND | Positive | 10-04-21 | Fatigue, headache, rhinorrhea, dysesthesias in legs and scapular area |
# 13 | Three layered cloth mask | 56/Female | Positive | ND | 11-04-21 | Fever, cough, chills, fatigue, headache, anosmia, ageusia, diarrhea |
# 14 | Surgical mask and safety glasses | 56/Female | ND | Positive | 12-04-21 | Fatigue, headache, back pain, cough, anosmia, ageusia |
# 15 | cloth mask | 48/Female | Positive | ND | 09-04-21 | Headache, fatigue, fever, cough, anosmia |
# 16 | Three layer cloth mask | 42/Female | Positive | ND | 16-04-21 | Fever, cough, chills, fatigue, headache |
# 17 | N95 and safety glasses | ND | ND | Negative | NA | No symptoms |
# 18 | Surgical mask and safety glasses | ND | ND | Negative | NA | No symptoms |
# 20 | Surgical mask | ND | ND | Negative | NA | No symptoms |
# 23 | Surgical mask | 63/Male | ND | Positive | 12-04-21 | Fever, cough, chills, fatigue, headache, respiratory distress, severe bacterial pneumonia |
# 24 | N95 and surgical mask | ND | ND | Negative | NA | No symptoms |
* ND: Not done/no data
** NA: Not applicable
For the qualitative detection of SARS-CoV-2, samples were tested using a rapid immunochromatographic assay for the viral nucleocapsid antigen, standard Q Covid-19 Ag test (SD Biosensor).
For the molecular detection viral RNA extraction was performed from samples using the QIAamp Viral RNA Mini Kit™ (Qiagen, Hilden, Germany). For molecular detection, the RNA extracts were amplified using qScript XLT 1-Step RT-qPCR Tough Mix™ (Quantabio Beverly, MA, USA) and the SARS- CoV-2 N1 primers of the US Centers for Disease Control (CDC) RT-PCR protocol (IDT, Coralville, lW, USA 7.
For viral isolation, Vero-E6 cells were seeded 24 hours before and a fraction of the nasopharyngeal samples (100 μl diluted in 250 μl DMEM) were inoculated over 75% confluent monolayers. Inoculum and cells were incubated at 37° C in 5% CO2 atmosphere for 90 minutes with gentle shaking every 30 minutes. The inoculum was removed and replaced with 1,5 ml DMEM medium containing 2% FBS and 1% penicillin-streptomycin. Cultures were monitored daily under the microscope to visualize the cytopathic effect 8. Viral RNA was extracted from supernatants, and the presence of SARS- CoV-2 on cultures was confirmed using qRT-PCR as explained above 9. This process was carried out to increase the number of viral particles per sample, improving the completeness of sequencing.
For the genomic characterization of the virus, next-generation sequencing was performed following the ARTIC protocol 10 at Corpogen Laboratories, Bogotá, Colombia. Briefly, amplicons were quantified and labeled with the Native Barcoding Kit EXPNBD104™ (Oxford Nanopore Technologies, Oxford, UK) and pooled in an equimolar amount. Genomic libraries were prepared with the SQK-LSK109™ 1D ligation kit (Oxford Nanopore Technologies) and sequenced using a FLO-MIN106-R9.4™ flow cell and the MinION™ instrument (Oxford Nanopore Technologies). Bases were identified using Guppy, version 3.2.2 ™ (Oxford Nanopore Technologies). The processed reads were aligned with the SARS-CoV-2 reference genome (GenBank NC_045512.2) using the BWA-MEM 14 algorithm and the BBMap 11 to generate the consensus sequence. The viral lineage was classified using PANGOLIN (Phylogenetic Assignment of Named Global Outbreak LINeages) 12.
For the phylogenetic analysis, the complete sequences associated with the outbreak and other 19 sequences from unrelated COVID-19 patients from Medellín were aligned with reference sequences of the original Wuhan 2019 isolate, variants of concern (VOC) and VOIs. Sequences identified as lineages B.1.111 and B.1.625 from the GISAID database [https://www.gisaid.org/ ] were also included because these lineages were highly prevalent in Medellín during 2021 4.
A total of 204 sequences were analyzed (dataset available from the authors upon request). The alignment by the MUSCLE algorithm and the selection of the substitution model by the Bayesian information criterion were carried out with MEGA 11 software 13. Phylogenetic analysis was performed by the maximum likelihood method on the IQ-TREE web server 14 with the GTR + G + I substitution model and an ultrafast bootstrap of 5,000 replicates. The resulting tree was visualized on the iTOL website 15.
This study was designed and conducted according to the Declaration of Helsinki and the Colombian legislation (Colombian Ministerio de Salud Resolution 008430, 1993). All subjects signed an informed consent. The collected biological material and demographic data were codified to ensure the privacy of the study participants.
Results
The vaccination appointment of the co-workers was scheduled for April 8, 2021, in a meeting room enabled for that purpose. Due to the logistics and requirements of vaccination, the workers stayed about an hour in the room, which had an area of 105 m2. That room did not have air conditioning, and its ventilation was limited to a system of windows and lattices. The distribution of the workers and the health personnel, the distance between rows and chairs, and the location of the index case are presented in figure 1. Everyone in the room wore a mask, although of different type and quality, such as cloth masks (one, two or three layers), surgical masks or N95 (table 1). There was an active conversation among most of the attendees, but physical contact was avoided.
Seven out of 24 co-workers attending the SARS-CoV-2 vaccination session developed COVID-19 clinical symptoms, four to ten days after the exposure. Symptoms included headaches, fever, chills, myalgia, cough and anosmia. Clinical evolution and virological data of the seven cases were variable, but symptomatology related to COVID-19 lasted around 14 days in most cases. Two cases presented with pneumonia, and one required hospitalization (table 1). The diagnosis was confirmed by antigen or viral genome detection in all cases; indeed, the secondary attack rate was 25% (95%CI: 9.8-46.7%). Subsequently, COVID-19 cases, one of them fatal, occurred in five relatives who had contact with two cases of the outbreak. The other six co-workers who underwent SARS-CoV-2 testing were negative for viral genome detection by RT-qPCR, and none of them presented symptoms (table 1).
The index case, and presumed source of this outbreak, was a female that was asymptomatic at the vaccination date but presented headache the next day; her mother had developed headache the day before the co-workers’ vaccination but it was assumed as a side effect of the COVID-19 vaccination that she received 96 hours before. Moreover, a niece of the index case also developed symptoms. The diagnosis of COVID-19 was laboratory confirmed in the index case and her family members 7 to 11 days after the mother’s vaccination (figure 2).
Positive viral isolation for SARS-CoV-2 was obtained from four of the workmates and additionaly from the mother of the index case. These isolates were subjected to whole genome sequencing. All genome sequences were preliminarily identified as lineage B.1.625 on the Nextclade web server tool 16. One of these genomes (case # 6) had low coverage (<50%) and was not included in the final analysis. The remaining four viral genome sequences from cases #13, #16, #23 and from the mother of the index case, are in GISAID database with access codes EPI_ISL_13902608, EPI_ ISL_13902607, EPI_ISL_13902609 and EPI_ISL_13902610, respectively. All had coverage greater than 81%; three of them were identical to each other, and the fourth (case #16) differed in only two positions.
In the inferred phylogenetic tree (figure 3), a clear differentiation of the lineage B.1.625 was observed; the four genomes associated with the outbreak formed a monophyletic group within the B.1.625 clade with bootstrap support of 100. These sequences showed the characteristic spike mutations of this lineage, including del69-70, T95I, del144, F157L, N440K, E484K, D614G, D950N and V1228L. Other sequences were obtained from patients attending health institutions in Medellín, but not associated with the outbreak, grouped with sequences of variants alpha, gamma, mu, delta, B.1.111 or B.1.625 in the phylogenetic analysis.
Discussion
We described the epidemiology, virology and molecular characteristics of an indoor SARS-CoV-2 outbreak. We identified seven cases of COVID-19 among the 24 co-workers attending a vaccination session, corresponding to a secondary attack rate of 25% (95% CI: 9.8-46.7%). The diagnosis of COVID-19 was also confirmed in five household contacts of two co-workers and two family members (mother and niece) of the index case. According to the contagion timeline, 13 cases were related to the mother of the index case. In turn, this 75-year-old woman may also have been infected during her vaccination that occurred in an overcrowded place five days before the vaccination of co-workers. Still, the details of this contagion were communicated informally and not thoroughly investigated (figure 2).
The logistics and biosecurity conditions of the vaccination sessions of the workmates were not appropriate to prevent the transmission of SARS-CoV-2, a respiratory virus usually transmitted by large respiratory droplets and aerosols. First of all, the vaccination session of co-workers was performed in a room with biosafety limitations such as suboptimal ventilation; the distance between rows was around two meters, but the distance between the chairs of the same row was only around one meter (figure 1). Moreover, the number of persons at the appointed place, the time spent in the room (30 to 90 minutes) and the active conversation among some attendees during the appointment, including the index case, could have facilitated the airborne transmission.
All vaccination attendees wore face masks at all times, however these were uneven in quality, ranging from single-layer cloth mask to N95s (table 1). The low number of exposed and infected individuals does not allow to draw conclusions about the relative efficacy of the various types of mask but it was notorious that infections occurred in people wearing all kinds of masks. Notwithstanding the foregoing, there is ample evidence that the N95 provides the best protection.
Although droplet and fomite transmission of SARS-CoV-2 were considered the most frequent modes for contagion at the beginning of the pandemic, several studies support the relevance of SARS-CoV-2 aerosol transmission. Evidence include super-spreading events, virions detection on the air, differences between outdoor and indoor transmission, detection of the virus in filters and ducts, cases in health workers despite using personal protection equipment that prevent droplet but not aerosol exposure and animal infection located in separately cages, among others 6. Indeed, virions of SARS- CoV-2 have been detected in aerosols 17-20, and a half-life of one to three hours of the virions in aerosols was estimated 21. Moreover, WHO and the US Centers for Disease Control and Prevention (CDC) recognize the airborne transmission of SARS-CoV-2 at short and long ranges 22,23.
Aerosols are particles (liquid, solid or semisolid) less than 5 pm in size that could stand suspended in the air for a while. These particles are normally generated during breathing, talking, laughing, singing, shouting, sneezing and coughing from individuals with or without respiratory infections. Furthermore, the conditions related to virus transmission by aerosols include the viral load, stability of the virions, size distribution of particles, electric charge, air/liquid interfacial properties and the composition of aerosols such as electrolytes, proteins and surfactants 6.
Variables to be considered for the route transmission by aerosol inhalation in this outbreak are the average temperature (21.5 oC) and relative humidity (63-73%) of Medellin 24, the indoor environment with suboptimal ventilation, the number of people per square meter, the time spent at the room, the distance between chairs and rows, and the active conversation among persons. Although other routes of transmission, such as transmission by direct contact or by fomites, cannot be ruled out, their probability would be very low since direct contact was limited and objects were not shared during the appointment.
The high nucleotide identity and the monophyletic grouping of the sequences of the three co-workers (cases # 16, # 13 and # 23) and the mother of the index case support a common source of contagion in this outbreak. The phylogenetic analysis of the viral sequences demonstrated the B.1.625 lineage of SARS-CoV-2. The Colombian Instituto Nacional de Salud described this variant for the first time in January, 2021 (https://github.com/cov-lineages/pango-designation/issues/93 ). Afterward, this variant was reported in countries such as Venezuela, Dominican Republic, Mexico, Aruba, USA, Germany, Spain and England (GISAID sequences up to 2021-05-25) 25.
In addition to the D614G mutation at the virion spike, exhibited in most circulating variants, and associated with greater infectivity, other spike substitutions and deletions (del) present in the sequences of this outbreak have been associated with some phenotypic trait: del 69-70, located at the N-terminal domain (NTD) is associated with greater transmissibility. Del 144, located at an NTD epitope formed by amino acids 140-156, is potentially related to immune escape. Two other observed mutations, N440K and E484K, are located at the receptor binding domain and potentially affect the affinity or the antigenicity of the virus; in particular, E484K has been associated with immune escape and increased affinity to the human ACE2 receptor 26. The substitution E484K has also been characterized in VOCs such as beta and gamma 27,28.
The Colombian genomic surveillance network for SARS-CoV-2 led by the Instituto Nacional de Salud reinforced the monitoring since January, 2021, because of the high probability of importation of circulating VOCs and VOIs. The approach was sequencing and genomic characterization of a probabilistic sample of COVID-19 cases from all regions of the country. The first sampling batch was performed between April 15th to June 15th, 2021, which coincided with the third and most severe wave of SARS-CoV-2 infection in Colombia.
A total of 1,630 samples from 27 regions/departments of Colombia were processed. Finally, 1,101 sequences were available in GISAID database. The phylogenetic analysis demonstrated the predominance of mu VOI (52,7%), followed by the gamma VOC (23.3%), B.1.625 variant (8.6%), and alpha VOC (5.7%).
This result indicated that variant B.1.625, causing the outbreak described in the present study, was a minority but still a circulating variant during the third epidemic wave in Antioquia. Interestingly, variant B.1.625 disappeared in the countrywide sampling carried out from September 15th to October 30th, 2021 (figure 4).
In summary, we provide epidemiological and molecular evidence of an outbreak of infection by SARS-CoV-2 variant B.1.625 acquired during an indoor vaccination session. Although we emphasize that the contagion occurred in an activity that, paradoxically, was intended to prevent the disease, we are not suggesting that vaccination is a risky practice by itself. Vaccination has been shown to be highly effective in reducing severity and mortality, as reported in the technical report number 3 “COHORTE ESPERANZA” presented by the Colombian Ministerio de Salud y Protección Social. Vaccination is a safe practice provided that appropriate biosafety measures are strictly followed during epidemic situations.